Recently, ulipristal acetate (GnRHa antagonist) shows promising effect on inhibiting leiomyoma fibrosis via decreasing TGF-β3 and its canonical signaling pathway as well as by limiting cell proliferation and ECM remodeling [36,63,64]. The gene discussed is TGFB3; the disease is leiomyoma.